^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Neuroblastoma

Related cancers:
16h
The MYCN 5' UTR as a therapeutic target in neuroblastoma. (PubMed, Cell Rep)
Finally, CMLD012824 led to growth inhibition in MYCN-amplified neuroblastoma models without generalized toxicity. Our studies highlight the key role of eIF4A1 in MYCN-amplified neuroblastoma and demonstrate the therapeutic potential of disrupting its function.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
21h
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma (clinicaltrials.gov)
P=N/A, N=75, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
22h
Autologous peripheral blood stem cell mobilization and apheresis in pediatric patients with cancer: A single-center report of 64 procedures. (PubMed, Pediatr Transplant)
Patients who had far less therapy before apheresis were more likely to mobilize successfully. Our study provides a detailed practice approach including complications during APSCA aiming to increase the success rates of apheresis in transplantation centers.
Retrospective data • Journal
|
CD34 (CD34 molecule) • PSCA (Prostate Stem Cell Antigen 2)
|
plerixafor
1d
Trial completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
|
Proleukin (aldesleukin) • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
2d
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma. (PubMed, Nat Commun)
It follows that the farnesyltransferase inhibitor (FTI) lonafarnib in addition to ALK TKIs act synergistically in neuroblastoma, inducing apoptosis in vitro. In particular, on combined treatment of neuroblastoma patient derived xenografts with an FTI and an ALK TKI complete regression of tumour growth is observed although tumours rapidly regrow on cessation of therapy. Overall, our data suggests that combined use of ALK TKIs and FTIs, constitutes a therapeutic approach to treat high risk neuroblastoma although prolonged therapy is likely required to prevent relapse.
Journal
|
ALK (Anaplastic lymphoma kinase) • MIR1304 (MicroRNA 1304)
|
ALK mutation
2d
Lineage specific transcription factor waves reprogram neuroblastoma from self-renewal to differentiation. (PubMed, Nat Commun)
Silencing the gained SOX4 SE using dCAS9-KRAB decreases SOX4 expression and attenuates ATRA-induced differentiation genes. Our study identifies oncogenic lineage drivers of NB self-renewal and TFs critical for implementing a differentiation program.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • GATA2 (GATA Binding Protein 2) • GATA3 (GATA binding protein 3) • SOX11 (SRY-Box Transcription Factor 11) • SOX4 (SRY-Box Transcription Factor 4)
2d
METTL14 promotes neuroblastoma formation by inhibiting YWHAH via an m6A-YTHDF1-dependent mechanism. (PubMed, Cell Death Discov)
Overall, our study provides valuable insights into the oncogenic effects of METTL14 in NB cells, highlighting its role in inhibiting YWHAH expression through an m6A-YTHDF1-dependent mechanism. These findings also suggest the potential utility of a biomarker panel for prognostic prediction in NB patients.
Journal
|
ETS1 (ETS Proto-Oncogene 1) • METTL14 (Methyltransferase 14) • YTHDF1 (YTH N6-Methyladenosine RNA Binding Protein 1) • YY1 (YY1 Transcription Factor)
3d
Dopamine‑iron homeostasis interaction rescues mitochondrial fitness in Parkinson's disease. (PubMed, Neurobiol Dis)
Importantly, dopamine treatment of PD neurons promoted a rescue effect by increasing mitochondrial respiration, activating antioxidant stress response, and normalizing altered metabolite levels linked to mitochondrial function. These observations provide evidence that dopamine affects iron homeostasis, intracellular stress responses and mitochondrial function in healthy cells, while dopamine supplementation can restore the disturbed regulatory network in PD cells.
Journal
|
TFRC • SNCA (Synuclein Alpha)
4d
Downregulation of ABLIM3 confers to the metastasis of neuroblastoma via regulating the cell adhesion molecules pathway. (PubMed, Comput Struct Biotechnol J)
RT-qPCR and western blot analyses demonstrated that downregulation of ABLIM3 led to decreased expression of ITGA3, ITGA8, and KRT19, the key components of CAMs. This study indicated that ABLIM3 can be an independent prognostic factor for NB patients, and CAMs may mediate the effect of ABLIM3 on the metastasis of NB, suggesting that ABLIM3 is a potential therapeutic target for NB metastasis, which provides a novel strategy for future research and treatment strategies for NB patients.
Journal • IO biomarker
|
KRT19 (Keratin 19) • ITGA3 (Integrin Subunit Alpha 3)
4d
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma (clinicaltrials.gov)
P2, N=24, Completed, Fundació Sant Joan de Déu | Unknown status --> Completed
Trial completion
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
Unituxin (dinutuximab) • Leukine (sargramostim)
7d
Neuroprotective potential of traditionally used medicinal plants of Manipur against rotenone-induced neurotoxicity in SH-SY5Y neuroblastoma cells. (PubMed, J Ethnopharmacol)
The plant extracts showed neuroprotective activities against rotenone-treated SH-SY5Y cells through antioxidant and anti-apoptotic mechanisms. These findings support for the ethnopharmacological uses of these plants in treating neurological disorders. They probably are a good source of neuroprotective compounds that could be further explored to develop treatment strategies for neurodegenerative diseases like Parkinson's disease.
Journal
|
CAT (Catalase)
8d
Inbraced: Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma (clinicaltrials.gov)
P1, N=44, Recruiting, University Hospital Southampton NHS Foundation Trust | Trial completion date: Nov 2023 --> Jul 2025 | Trial primary completion date: Nov 2023 --> Sep 2024
Trial completion date • Trial primary completion date
|
PD-L1 expression
|
Opdivo (nivolumab) • Qarziba (dinutuximab beta) • Azedra (iobenguane I 131)
8d
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (clinicaltrials.gov)
P2, N=5, Active, not recruiting, National Cancer Institute (NCI) | N=49 --> 5 | Trial completion date: Sep 2027 --> Apr 2025 | Trial primary completion date: Sep 2027 --> Mar 2024
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
Zarnestra (tipifarnib)
9d
Oleoylethanolamide and Palmitoylethanolamide Enhance IFNβ-Induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells. (PubMed, Molecules)
Furthermore, GW6471, a PPARα inhibitor, and the genetic silencing of the receptor were shown to lower PD-L1 and cleaved PARP levels. These results reveal the presence of a novel mechanism, independent of the IFNβ-prompted pathway, by which OEA and PEA can directly impair cell survival, proliferation, and clonogenicity through modulating and potentiating the intrinsic apoptotic pathway in human SH-SY5Y cells.
Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IFNB1 (Interferon Beta 1) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
|
PD-L1 expression
9d
HN1 is a novel dedifferentiation factor involved in regulating the cell cycle and microtubules in SH-SY5Y neuroblastoma cells. (PubMed, J Cell Biochem)
Moreover, HN1 expression is also correlated with the microtubule stability in SH-SY5Y cells, which was investigated with nocodazole and taxol treatments...Moreover, cell cycle dynamics also changed upon HN1 overexpression with alternating effects on SH-SY5Y and RA-differentiated (N-type) cells. Therefore, HN1 is a potential cell cycle regulatory element in the development of neuroblastoma or dedifferentiation of neurons, which requires further studies to decipher its mechanistic role.
Journal
|
JPT1 (Jupiter Microtubule Associated Homolog 1)
|
paclitaxel
9d
NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
P2, N=42, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Sep 2024
Trial completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IL6 (Interleukin 6) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
|
MYCN amplification • IL6 expression
|
cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane
10d
Mitotic gene regulation by the N-MYC-WDR5-PDPK1 nexus. (PubMed, BMC Genomics)
Overall, we identify a small group of genes highly enriched within functional gene categories related to mitotic processes that are commonly regulated by N-MYC, WDR5, and PDPK1 and suggest that a tripartite interaction between the three regulators may be responsible for setting the level of mitotic gene regulation in N-MYC amplified cell lines. This study provides a foundation for future studies to determine the exact mechanism by which N-MYC, WDR5, and PDPK1 converge on cell cycle related processes.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • WDR5 (WD Repeat Domain 5) • PDPK1 (3-Phosphoinositide dependent protein kinase 1)
|
MYCN amplification • MYC overexpression • MYC expression
10d
Correlation of BARD1 gene polymorphisms with risk of neuroblastoma: a meta-analysis. (PubMed, Nucleosides Nucleotides Nucleic Acids)
BARD1 polymorphisms might be significantly associated with NB susceptibility. It is crucial that these finding should be further confirmed through extensive and well-planned studies.
Retrospective data • Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BARD1 (BRCA1 Associated RING Domain 1)
11d
18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) imaging of pediatric neuroblastoma: a multi-omics parameters method to predict MYCN copy number category. (PubMed, Quant Imaging Med Surg)
A retrospective analysis was performed on 104 pediatric patients with NB that had been confirmed by pathology...Post hoc analysis revealed the great potential of the M-model in differentiating MYCN gain from MNA (AUC 0.95, 95% CI: 0.89-1). The M-model model based on bio-omics and radiomics features is an effective tool to distinguish MYCN copy number category in pediatric patients with NB.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
11d
Choosing T-cell sources determines CAR-T cell activity in neuroblastoma. (PubMed, Front Immunol)
Moreover, ex vivo culture with IL-7+IL-15+IL-21 could favor CAR-T products with a longer persistence in the host. Our strategy may complement the current use of Dinutuximab in treating NB through its combination with a targeted CAR-T cell approach.
Journal • CAR T-Cell Therapy
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2 (Interleukin 2) • IL15 (Interleukin 15) • IL21 (Interleukin 21) • IL7 (Interleukin 7)
|
Unituxin (dinutuximab)
13d
Differential Competitive Growth of Transgenic Subclones of Neuroblastoma Cells Expressing Different Levels of Cathepsin D Co-Cultured in 2D and 3D in Response to EGF: Implications in Tumor Heterogeneity and Metastasis. (PubMed, Cancers (Basel))
The present findings support the view that during NB growth on a substrate or when spreading as floating neurospheres, CD expression is epigenetically modulated to confer survival advantage. Thus, epigenetic targeting of CD could represent an additional strategy to prevent NB metastases.
Journal
|
CDH1 (Cadherin 1) • CDH2 (Cadherin 2) • CTSD (Cathepsin D)
|
CDH1 expression
13d
Predictive value of 18 F-FDG PET/CT versus bone marrow biopsy and aspiration in pediatric neuroblastoma. (PubMed, Clin Exp Metastasis)
18 F-FDG-PET/CT is a valuable method for evaluating BMM in NB. The routine practice of performing a BMBA without discrimination may need to be reassessed. Negative result from 18 F-FDG-PET/CT could potentially spare children with invasive bone marrow biopsies.
Journal • FDG PET • Biopsy
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification • MYCN positive
14d
Bilateral adrenal neuroblastoma: peculiar pattern of a rare pediatric presentation. (PubMed, Discov Oncol)
BSN treatment is similar to unilateral disease. A more conservative surgical approach with adrenal tissue preservation on less extensive side should be considered. Biological variables and extent of disease are amongst the most important prognostic determinants. Future studies are warranted to further address the biologic profiling of BSN and highlight prognostic significance of size difference between both adrenal sides.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
15d
Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions. (PubMed, Front Cell Dev Biol)
Recent studies of immunotherapeutic agents used in NB are also studied in this article. Moreover, we explore potential future directions to discover new targets and treatments to enhance existing therapies and ultimately improve treatment outcomes and survival rates for NB patients.
Review • Journal • IO biomarker
|
ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
15d
Development and validation of a novel nomogram for predicting overall survival patients with neuroblastoma. (PubMed, Eur J Surg Oncol)
The nomogram we constructed exhibited good predictive performance and could be used to assist clinicians in their decision-making process.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
16d
Abemaciclib and Vacuolin-1 decrease aggregate-prone TDP-43 accumulation by accelerating autophagic flux. (PubMed, Biochem Biophys Rep)
A treatment with the VPS34 inhibitor wortmannin (WM) suppressed Abe-/Vac-facilitated autophagic flux and the degradation of GFP-tagged aggregate-prone TDP-43. Collectively, these results suggest that Abe and Vac degrade aggregate-prone TDP-43 by accelerating autophagosome formation and autophagosome-lysosome fusion through the formation of PI(3)P.
Journal
|
LAMP1 (Lysosomal Associated Membrane Protein 1) • TARDBP (TAR DNA Binding Protein) • TSG101 (Tumor Susceptibility 101)
|
LAMP1 expression
|
Verzenio (abemaciclib)
16d
Protective effect of Ganoderma lucidum-fermented crop extracts against hydrogen peroxide- or β-amyloid-induced damage in human neuronal SH-SY5Y cells. (PubMed, BMC Complement Med Ther)
These results clearly confirmed the effects of G. lucidum-fermented crop extracts on preventing against H2O2- or Aβ25-35-induced neuronal cell death and inhibiting AChE activity, revealing their potential in management of AD.
Journal
|
CAT (Catalase)
16d
NTRK3 exhibits a pro-oncogenic function in upper tract urothelial carcinomas. (PubMed, Kaohsiung J Med Sci)
Furthermore, the overexpression of NTRK3 in UM-UC-14 cells promoted AKT-mTOR pathway activity, cellular migration, and cell invasion. From these observations, we concluded that NTRK3 may contribute to aggressive behaviors in UTUC by facilitating cell migration and invasion through its interaction with the AKT-mTOR pathway and the expression of NTRK3 is a potential predictor of clinical outcomes in cases of UTUC.
Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK expression
16d
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers. (PubMed, Clin Cancer Res)
Finally, we established GMP-compliant manufacturing of GD2IL18CART and found it to be feasible and efficient at clinical scale. These results pave the way for clinical investigation of GD2IL18CART in pediatric and adult patients with neuroblastoma and other GD2-positive cancers (EU CT 2022-501725-21-00).
Preclinical • Journal • CAR T-Cell Therapy
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL18 (Interleukin 18)
17d
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis. (PubMed, Alzheimers Res Ther)
Our findings support a major role for CatD in the proteostasis of both Aβ and tau in vivo. To our knowledge, the CatD-KO mouse line is the only model to develop detectable Aβ accumulation and profound tauopathy in the absence of overexpression of hAPP or human tau with disease-associated mutations. Given that tauopathy emerges from disruption of CatD, which can itself be potently inhibited by Aβ42, our findings suggest that impaired CatD activity may represent a key mechanism linking amyloid accumulation and tauopathy in AD.
Journal
|
APP (Amyloid Beta Precursor Protein) • CTSD (Cathepsin D) • MAPT (Microtubule Associated Protein Tau)
17d
STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
P1, N=44, Recruiting, Seattle Children's Hospital | Trial completion date: Jun 2038 --> Jun 2040 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression
|
EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19
17d
Indoxyl sulphate-TNFα axis mediates uremic encephalopathy in rodent acute kidney injury. (PubMed, Acta Pharmacol Sin)
In this study we investigated the CNS behaviors and expression/function of BBB OAT3 in AKI rats and mice, which received intraperitoneal injection of cisplatin 8 and 20 mg/kg, respectively...The alterations caused by TNFα and CMs in vitro, and by AKI and TNFα in vivo were abolished by infliximab, a monoclonal antibody designed to intercept and neutralize TNFα, suggesting that AKI impaired the expressions of OAT3, synaptophysin and MAP2 in the brain via IS-induced TNFα release from macrophages or microglia (termed as IS-TNFα axis)...We conclude that AKI inhibits the expressions of OAT3, synaptophysin and MAP2 due to IS-induced TNFα release from macrophages or microglia. TNFα impairs the expressions of OAT3, synaptophysin and MAP2 partly via activating NF-κB pathway and inhibiting Nrf2-HO-1 pathway.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • SYP (Synaptophysin) • RELA (RELA Proto-Oncogene)
|
RELA expression
|
cisplatin
18d
Monocarboxylate Transporters 1 and 2 Are Responsible for L-Lactate Uptake in Differentiated Human Neuroblastoma SH-SY5Y Cells. (PubMed, Biol Pharm Bull)
In this study, we demonstrated that MCT1 and 2 are major contributors to L-lactate transport in differentiated human neuroblastoma SH-SY5Y cells from the viewpoint of kinetic analysis. These results lead to a better understanding of ANLS in humans, and further exploration of the factors that can promote MCT1 and 2 functions is required.
Journal
|
MCT1 (SLC16A1)
20d
Different concentrations of adapalene induce differentiation and apoptosis of SH-SY5Y cells (PubMed, Zhongguo Dang Dai Er Ke Za Zhi)
Low concentrations of adapalene can induce differentiation of SH-SY5Y cells into mature functional neurons, while high concentrations of adapalene can induce apoptosis in SH-SY5Y cells.
Journal
|
NEFH (Neurofilament Heavy)
21d
Exploring neuroadaptive cellular pathways in chronic morphine exposure: An in-vitro analysis of cabergoline and Mdivi-1 co-treatment effects on the autophagy-apoptosis axis. (PubMed, J Cell Biochem)
The impact of Methadone, Cabergoline, and a combination of Cabergoline and Mdivi-1 on the cellular and molecular responses associated with Morphine-induced changes was studied in human Neuroblastoma (SK-N-MC) and Glioblastoma (U87-MG) cell lines that were exposed to prolong Morphine treatment. This highlights the potential for new treatments in the DRD2 pathway and underscores the importance of investigating the interplay between autophagy and apoptosis to advance research in managing cancer-related pain. The study necessitates an in-depth investigation into the relationship between autophagy and apoptosis, with a specific emphasis on protein interactions and the dynamics of cell signaling.
Preclinical • Journal
|
PCNA (Proliferating cell nuclear antigen) • DRD2 (Dopamine Receptor D2)
21d
Molecular-Guided Therapy for Childhood Cancer (clinicaltrials.gov)
P=N/A, N=186, Completed, Giselle Sholler | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jan 2024 | Trial primary completion date: Jun 2025 --> Jan 2024
Trial completion • Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
21d
Ergosterol promotes neurite outgrowth, inhibits amyloid-beta synthesis, and extends longevity: In vitro neuroblastoma and in vivo Caenorhabditis elegans evidence. (PubMed, Life Sci)
Ergosterol is a potential candidate compound that might benefit AD patients by promoting neurite outgrowth, inhibiting Aβ synthesis, and enhancing longevity.
Preclinical • Journal
|
TENM4 (Teneurin Transmembrane Protein 4)
21d
Regulating Lars2 in mitochondria: A potential Alzheimer's therapy by inhibiting tau phosphorylation. (PubMed, Neurotherapeutics)
Additionally, immunofluorescence assays indicated an increase in p-tau, atrophy in the hippocampal region, and a decrease in neurons following Lars2 knockout. Taken together, our findings indicate that Lars2 represents a promising therapeutic target for AD.
Journal
|
LARS2 (Leucyl-TRNA Synthetase 2)
22d
PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin. (PubMed, J Pediatr Surg)
The correlation between PIM and ABCC1 gene expression suggests PIM kinases may contribute to neuroblastoma chemotherapeutic resistance. PIM kinase inhibition increased intracellular doxorubicin accumulation. Combination treatment with AZD1208 and doxorubicin decreased neuroblastoma cell viability in a synergistic fashion. These findings support further investigations of PIM kinase inhibition in neuroblastoma.
Journal
|
ABCC1 (ATP Binding Cassette Subfamily C Member 1) • PIM1 (Pim-1 Proto-Oncogene) • PIM3 (Pim-3 Proto-Oncogene)
|
doxorubicin hydrochloride • AZD1208
24d
Supratentorial neuroepithelial tumor with PLAGL1 gene fusion - a new type of morphologically variable pediatric brain neoplasm defined by a distinct DNA methylation class. A case report and literature review (PubMed, Zh Vopr Neirokhir Im N N Burdenko)
Methylation analysis in neurooncology is essential for unclear tumor morphology or divergence between histological and clinical data. In our case, this technique confirmed benign nature of tumor, and we preferred follow-up without unnecessary adjuvant treatment.
Review • Journal • Epigenetic controller
|
EWSR1 (EWS RNA Binding Protein 1)
24d
NCS-1 protein regulates TRPA1 channel through the PI3K pathway in breast cancer and neuronal cells. (PubMed, J Physiol Biochem)
These results contribute to understanding how Ca2+ homeostasis is regulated and provides a mechanism underlying conditions where Ca2+ dynamics are compromised, including breast cancer. With a cellular pathway identified, targeted treatments can be developed for breast cancer and neuropathy, among other related diseases.
Journal
|
TRPA1 (Transient Receptor Potential Cation Channel Subfamily A Member 1)
24d
Extracranial Vascular Anomalies Driven by RAS/MAPK Variants: Spectrum and Genotype-Phenotype Correlations. (PubMed, J Am Heart Assoc)
This comparison of patients with various PVs in genes of the RAS/MAPK pathway provides potential associations with certain morphological and clinical phenotypes. RAS variants were associated with more aggressive phenotypes, generating preliminary data and hypothesis for future larger studies.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • RAS (Rat Sarcoma Virus)